Appili Therapeutics Inc.
APLIF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $104 | $0 | -$13 | $108 |
| % Growth | – | 100% | -111.6% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $104 | $0 | -$13 | $108 |
| % Margin | 100% | – | 100% | 100% |
| R&D Expenses | $838 | $961 | $1,530 | $1,728 |
| G&A Expenses | $564 | $642 | $992 | $443 |
| SG&A Expenses | $564 | $642 | $992 | $443 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$223 | -$551 | -$2,472 | -$2,560 |
| Operating Expenses | $1,180 | $1,053 | $49 | -$389 |
| Operating Income | -$1,076 | -$1,053 | -$62 | $497 |
| % Margin | -1,034.9% | – | 490.3% | 458.7% |
| Other Income/Exp. Net | $121 | -$166 | $317 | -$1,031 |
| Pre-Tax Income | -$954 | -$1,219 | $256 | -$534 |
| Tax Expense | $35 | $31 | $28 | -$10 |
| Net Income | -$989 | -$1,250 | $228 | -$524 |
| % Margin | -951.6% | – | -1,809.1% | -483.9% |
| EPS | -0.01 | -0.01 | 0.002 | -0.004 |
| % Growth | 2.9% | -642.1% | 144.2% | – |
| EPS Diluted | -0.01 | -0.01 | 0.002 | -0.004 |
| Weighted Avg Shares Out | 121,266 | 121,266 | 121,273 | 121,273 |
| Weighted Avg Shares Out Dil | 121,266 | 121,266 | 121,266 | 121,266 |
| Supplemental Information | – | – | – | – |
| Interest Income | $218 | $0 | $0 | $0 |
| Interest Expense | $0 | $486 | $670 | $522 |
| Depreciation & Amortization | $3 | $4 | $3 | $4 |
| EBITDA | -$1,072 | -$729 | $928 | -$8 |
| % Margin | -1,031.7% | – | -7,365.1% | -7.6% |